BR112012010333A2 - peptídeos terapêuticos - Google Patents

peptídeos terapêuticos

Info

Publication number
BR112012010333A2
BR112012010333A2 BR112012010333A BR112012010333A BR112012010333A2 BR 112012010333 A2 BR112012010333 A2 BR 112012010333A2 BR 112012010333 A BR112012010333 A BR 112012010333A BR 112012010333 A BR112012010333 A BR 112012010333A BR 112012010333 A2 BR112012010333 A2 BR 112012010333A2
Authority
BR
Brazil
Prior art keywords
substitution
groups
amino acid
group
cyclic
Prior art date
Application number
BR112012010333A
Other languages
English (en)
Inventor
Martina Havelkova
Morten Strom
Terkel Hansen
Veronika Torfoss
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of BR112012010333A2 publication Critical patent/BR112012010333A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

peptídeo terapêuticos. a presente invenção proporciona um peptídeo, peptidomimético ou derivado de amino ácido tendo uma carga positiva líquida de pelo menos +2, e incorporando um beta amino ácido disubstituído, cada um dos grupos de substituição no beta amino ácido, que pode ser o mesmo ou diferente, compreende pelo menos (7) átomos de não-hidrogênio, é lipofílico, e tem pelo menos um grupo cíclico, um ou mais grupos cíclicos dentro de um grupo de substituição pode ser ligado ou fundido a um ou mais grupos cíclicos dentro do outro grupo se substituição, e onde os grupos cíclicos são fundidos dessa maneira ao número total combinado de átomos de não-hidrogênio para os dois grupos de substituição é pelo menos (12), para uso como um agente terapêutico citilítico; bem como usos não-terapêuticos destas moléculas e certos novos compostos definidos de dentro desta definição.
BR112012010333A 2009-11-02 2010-11-02 peptídeos terapêuticos BR112012010333A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds
PCT/GB2010/002024 WO2011051692A1 (en) 2009-11-02 2010-11-02 Therapeutic peptides

Publications (1)

Publication Number Publication Date
BR112012010333A2 true BR112012010333A2 (pt) 2016-03-29

Family

ID=41435032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010333A BR112012010333A2 (pt) 2009-11-02 2010-11-02 peptídeos terapêuticos

Country Status (15)

Country Link
US (1) US8809280B2 (pt)
EP (1) EP2496596B1 (pt)
JP (1) JP5810090B2 (pt)
KR (1) KR101730680B1 (pt)
CN (1) CN102762586B (pt)
AU (1) AU2010311186B2 (pt)
BR (1) BR112012010333A2 (pt)
CA (1) CA2777749C (pt)
DK (1) DK2496596T3 (pt)
ES (1) ES2621188T3 (pt)
GB (1) GB0919194D0 (pt)
NZ (1) NZ599791A (pt)
PL (1) PL2496596T3 (pt)
RU (2) RU2676713C2 (pt)
WO (1) WO2011051692A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2813512T3 (da) 2011-12-28 2021-04-26 Chugai Pharmaceutical Co Ltd Fremgangsmåde til cyklisering af en peptidforbindelse
WO2016148044A1 (ja) 2015-03-13 2016-09-22 中外製薬株式会社 改変アミノアシルｔＲＮＡ合成酵素およびその用途
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
EP3444264A4 (en) * 2016-04-14 2020-03-18 TAO Health Life Pharma Co., Ltd. PEPTIDE FOR AMYLOSPHEROID BINDING INHIBITION (ASPD), AND ASSESSMENT AND SCREENING METHOD
GB201705255D0 (en) * 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds
WO2018188761A1 (en) 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
JP7229158B2 (ja) 2017-06-09 2023-02-27 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
WO2019117274A1 (ja) 2017-12-15 2019-06-20 中外製薬株式会社 ペプチドの製造方法、及び塩基の処理方法
US11732002B2 (en) 2018-11-30 2023-08-22 Chugai Seiyaku Kabushiki Kaisha Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound
CN110294793B (zh) * 2019-06-24 2023-10-27 合肥科生景肽生物科技有限公司 Sumo荧光探针及其制备方法
CN114790151B (zh) * 2022-02-14 2023-03-31 湖南省湘中制药有限公司 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342705A (en) 1979-11-23 1982-08-03 Monsanto Company Methylene thioethers
GR79206B (pt) 1982-06-03 1984-10-22 Montedison Spa
IT1161927B (it) 1983-03-31 1987-03-18 Montedison Spa Furano-derivati ad attivita' fungicida
DK523288A (da) 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
US5593967A (en) 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
WO1992004045A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Novel cholecystokinin antagonists, their preparation and therapeutic use
US5387671A (en) 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5885782A (en) 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
RO117913B1 (ro) 1996-01-02 2002-09-30 Aventis Pharmaceuticals Inc. Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
DE102006018080A1 (de) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
ES2532392T3 (es) * 2006-07-10 2015-03-26 Pba3 Biomed Gmbh Péptidos antimicrobianos
GB0724951D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
ATE482186T1 (de) * 2008-03-18 2010-10-15 Univ Dresden Tech Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion

Also Published As

Publication number Publication date
RU2015111706A3 (pt) 2018-10-29
RU2676713C2 (ru) 2019-01-10
RU2548905C2 (ru) 2015-04-20
KR101730680B1 (ko) 2017-04-26
RU2012121264A (ru) 2013-12-10
EP2496596B1 (en) 2017-01-11
JP5810090B2 (ja) 2015-11-11
CN102762586B (zh) 2016-10-05
AU2010311186B2 (en) 2015-09-24
ES2621188T3 (es) 2017-07-03
PL2496596T3 (pl) 2017-08-31
GB0919194D0 (en) 2009-12-16
WO2011051692A1 (en) 2011-05-05
CN102762586A (zh) 2012-10-31
DK2496596T3 (en) 2017-04-03
AU2010311186A1 (en) 2012-05-31
US20130035296A1 (en) 2013-02-07
CA2777749A1 (en) 2011-05-05
EP2496596A1 (en) 2012-09-12
RU2015111706A (ru) 2015-11-10
KR20120104986A (ko) 2012-09-24
CA2777749C (en) 2019-08-06
US8809280B2 (en) 2014-08-19
JP2013509389A (ja) 2013-03-14
NZ599791A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
BR112012010333A2 (pt) peptídeos terapêuticos
Zhou et al. Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
BR112017019779A2 (pt) composto, e, composição farmacêutica
BR112015004997A2 (pt) composições contendo misturas de alcanos semifluorados
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
AR091649A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ECSP11011367A (es) Composición farmacéutica
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
EA201590709A1 (ru) Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
ECSP109968A (es) Depsipéptidos cíclicos
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR112018000909A2 (pt) imunoconjugados de il22
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal